Scientists have identified three types of vaccine-induced antibodies that can neutralize diverse strains of influenza virus that infect humans. The discovery will help guide development of a universal influenza vaccine, according to investigators at the National Institute of Allergy and Infectious Diseases (NIAID), and the National Human Genome Research Institute (NHGRI), both part of the National Institutes of Health (NIH), and collaborators who conducted the research. The findings appear in the July 21st online edition of Cell.

The seasonal influenza vaccine must be updated each year because flu viruses mutate. However, the stem region of the virus typically remains unchanged, making it an ideal target for antibodies induced by a universal flu vaccine. Such a vaccine would be effective against multiple subtypes of influenza and therefore would eliminate the need to update the vaccine each year. Until now, scientists had only identified broadly neutralizing antibodies targeting the flu virus stem in humans following natural infection. The new research provides clear evidence that these antibodies can be induced by a vaccine.

The investigators examined blood samples from six people who had received a vaccine against H5N1 influenza, commonly known as the bird flu virus. In the blood samples they identified B cells (a type of white blood cell that responds to infection by secreting antibodies) that reacted to various subtypes of influenza virus, and then characterized and classified the cells’ antibody genetic sequences. The scientists discovered the B cells encoded three classes of antibodies — seen among multiple participants — that can neutralize diverse influenza virus subtypes and, therefore, could form the basis of a universal flu vaccine. Researchers can now use the B cell sequencing information they identified to quickly and accurately measure immune responses among participants in future influenza vaccine trials, according to the authors.

The above post is reprinted from materials provided by NIH/National Institute of Allergy and Infectious Diseases. Note: Materials may be edited for content and length.


M. Gordon Joyce, Adam K. Wheatley, Paul V. Thomas, Gwo-Yu Chuang, Cinque Soto, Robert T. Bailer, Aliaksandr Druz, Ivelin S. Georgiev, Rebecca A. Gillespie, Masaru Kanekiyo, Wing-Pui Kong, Kwanyee Leung, Sandeep N. Narpala, Madhu S. Prabhakaran, Eun Sung Yang, Baoshan Zhang, Yi Zhang, Mangaiarkarasi Asokan, Jeffrey C. Boyington, Tatsiana Bylund, Sam Darko, Christopher R. Lees, Amy Ransier, Chen-Hsiang Shen, Lingshu Wang, James R. Whittle, Xueling Wu, Hadi M. Yassine, Celia Santos, Yumiko Matsuoka, Yaroslav Tsybovsky, Ulrich Baxa, James C. Mullikin, Kanta Subbarao, Daniel C. Douek, Barney S. Graham, Richard A. Koup, Julie E. Ledgerwood, Mario Roederer, Lawrence Shapiro, Peter D. Kwong, John R. Mascola, Adrian B. McDermott. Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. Cell, 2016; DOI: 10.1016/j.cell.2016.06.043